ReviewTranslational research : the journal of laboratory and clinical medicine2021
Influence of immunomodulatory drugs on the gut microbiota.
Review in Translational research : the journal of laboratory and clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Checkpoint inhibitor responses can be regulated by the gut microbiota - A systematic review.Neoplasia (New York, N.Y.) · 2023Pooled it
- Decoding the gut microbiota-immune dialogue: from bidirectional axis to therapeutic applications.Journal of nanobiotechnology · 2026Review
- Dysbiosis of gut microbiota and metabolomic alterations in myasthenia gravis: insights from 16S rRNA sequencing and untargeted metabolomics.Frontiers in immunology · 2026Article
- An overview of the role of the gut microbiota in rheumatoid arthritis.Microbiome research reports · 2026Review
- Dietary composition modulate gut microbiota and related biomarkers in patients with chronic kidney disease.Scientific reports · 2025Article
- Gut-immune-brain interactions during neurodevelopment: from a brain-centric to a multisystem perspective.BMC medicine · 2025Review
- AI-driven multi-omics profiling of sepsis immunity in the digestive system.Frontiers in immunology · 2025Review
- Bioactive components and delivery strategies of food-medicine homologous substances in lung cancer therapy: current advances and clinical translation.Frontiers in nutrition · 2025Review
- Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Review
- Clinical Perspectives of Gut Microbiota in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: Where Do We Stand?Biomedicines · 2023Review
- Interleukin-35 -producing B cells rescues inflammatory bowel disease in a mouse model via STAT3 phosphorylation and intestinal microbiota modification.Cell death discovery · 2023Article
- Inflammation, Lifestyle Factors, and the Microbiome-Gut-Brain Axis: Relevance to Depression and Antidepressant Action.Clinical pharmacology and therapeutics · 2023Review
- Anti-cancer activity of human gastrointestinal bacteria.Medical oncology (Northwood, London, England) · 2022Review
- Possible Interactions between Malaria, Helminthiases and the Gut Microbiota: A Short Review.Microorganisms · 2022Review
- The role of bacterial translocation in sepsis: a new target for therapy.Therapeutic advances in gastroenterology · 2022Review
- Application of NGS Technology in Understanding the Pathology of Autoimmune Diseases.Journal of clinical medicine · 2021Review
- Exploring the Modulatory Effects of Gut Microbiota in Anti-Cancer Therapy.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Immunomodulatory medications are a mainstay of treatment for autoimmune diseases and malignancies. In addition to their direct effects on immune cells, these medications also impact the gut microbiota. Drug-induced shifts in commensal microbes can lead to indirect but important changes in the immune response. We performed a comprehensive literature search focusing on immunotherapy/microbe interactions. Immunotherapies were categorized into 5 subtypes based on their mechanisms of action: cell trafficking inhibitors, immune checkpoint inhibitors, immunomodulators, antiproliferative drugs, and inflammatory cytokine inhibitors. Although no consistent relationships were observed between types of immunotherapy and microbiota, most immunotherapies were associated with shifts in specific colonizing bacterial taxa. The relationships between colonizing microbes and drug efficacy were not well-studied for autoimmune diseases. In contrast, the efficacy of immune checkpoint inhibitors for cancer was tied to the baseline composition of the gut microbiota. There was a paucity of high-quality data; existing data were generated using heterogeneous sampling and analytic techniques, and most studies involved small numbers of participants. Further work is needed to elucidate the extent and clinical significance of immunotherapy effects on the human microbiome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.